Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia - Test2 - elhamkhani - TriplyDB

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

http://www.wikidata.org/entity/Q27674674

about

The basal transcription machinery as a target for cancer therapy Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting Histone recognition and large-scale structural analysis of the human bromodomain family Down-regulation of NF-κB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer Small-molecule inhibition of BRDT for male contraception.Process of Fragment-Based Lead Discovery-A Perspective from NMR Studying epigenetic complexes and their inhibitors with the proteomics toolbox Epigenetics and inheritance of phenotype variation in livestock Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System Tumors The Impact of External Factors on the Epigenome: In Utero and over Lifetime DNA Methylation and Chromatin Remodeling: The Blueprint of Cancer Epigenetics Drug Delivery Using Nanoparticles for Cancer Stem-Like Cell Targeting Epigenetic regulators and their impact on therapy in acute myeloid leukemia Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance Minireview: Conversing with chromatin: the language of nuclear receptors Bromodomain proteins in HIV infection Design of small molecule epigenetic modulators Mutual relationships between transcription and pre-mRNA processing in the synthesis of mRNA Mechanisms of epigenetic regulation of leukemia onset and progression Recent progress toward epigenetic therapies: the example of mixed lineage leukemia Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy Chromatin targeting drugs in cancer and immunity Cancer epigenetics drug discovery and development: the challenge of hitting the mark Hijacked in cancer: the KMT2 (MLL) family of methyltransferases Proteomics in epigenetics: new perspectives for cancer research Protein lysine acetylation by p300/CBP Getting up to speed with transcription elongation by RNA polymerase II Bromodomain Proteins Contribute to Maintenance of Bloodstream Form Stage Identity in the African Trypanosome Identification of a Chemical Probe for Bromo and Extra C-Terminal Bromodomain Inhibition through Optimization of a Fragment-Derived Hit Optimization of 3,5-Dimethylisoxazole Derivatives as Potent Bromodomain Ligands Cyclin-Dependent Kinase Inhibitor Dinaciclib Interacts with the Acetyl-Lysine Recognition Site of Bromodomains BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models Discovery of Novel Small-Molecule Inhibitors of BRD4 Using Structure-Based Virtual Screening Structure-Guided Design of Potent Diazobenzene Inhibitors for the BET Bromodomains The double PHD finger domain of MOZ/MYST3 induces -helical structure of the histone H3 tail to facilitate acetylation and methylation sampling and modification RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain Structural Insights into Acetylated-Histone H4 Recognition by the Bromodomain-PHD Finger Module of Human Transcriptional Coactivator CBP

P2860

Q21246017-06D4C075-E749-4515-9375-DF37A27EB50F Q24308867-76C6CE4A-7F65-4BB5-AE22-C72BFFEAA448 Q24310431-C7D48405-6913-49E9-9AC4-C09847BADA7B Q24337006-AD94B6F0-0662-4B42-B806-A6B68F155DE1 Q24337204-96FBD429-CF55-4609-8F83-C082AFEB4E05 Q24616901-C9912446-6BD1-41D9-A22F-8939A0366FED Q26738768-7F11E981-F919-47A2-ABF4-A3842228F4D9 Q26738885-CDA636EC-12B3-426C-9DCC-B86FC01F27DA Q26742131-0203D5D9-B078-411A-BBA1-45515A0F7E2B Q26744080-240A9D59-AFDA-4D00-81C8-CFD1BDFF36F6 Q26744268-113B236E-EAA2-438C-8CFD-F2DA6D489EAB Q26746703-F220C182-02F1-4A10-B88D-C5533250A213 Q26749421-6120E3A9-C36D-494E-B99B-BEAFF321F356 Q26752688-25CF607F-0221-4D13-A1D6-FF227ACED383 Q26765402-360E54AB-EADF-4BC9-A619-D2D910DBC0EE Q26776393-5483B455-FAE0-4E8E-BC16-B011112BEB04 Q26829103-03737F27-4B6E-47E2-8AA5-288B0D7F0201 Q26829860-C823D149-3E78-4D03-992E-7D5FE82F0AE6 Q26850027-BBBB54F2-7C46-419A-A327-BC587032D8BF Q26851218-1C57324E-EDE3-471B-88EA-423F08D80BBB Q26861785-BBE46E43-1B45-4C10-9C7A-88D738FE9E32 Q26863577-02BF5352-112E-435F-866C-9DEE713CB965 Q26865149-983CACB3-0044-4005-8994-42219F39AEBD Q26991736-7D5E18B9-BF9E-4773-9105-765DB28CC630 Q26999888-896FA357-F622-4631-AC26-1ADE6410D302 Q27002333-DF9266F3-59C2-4106-9F35-ADE0709D3306 Q27006839-2F473B83-7AAA-4DB0-9684-8DF1F034CA56 Q27014943-6CCC22F3-51F2-455D-AFB1-B55E1971BDEE Q27021749-32C122C2-6AB6-4DA7-92D2-6CA0B9BAF872 Q27023288-BD00F56B-73F0-4E96-BB3E-4AF652D9CC29 Q27345564-3ECA6D50-3E02-4620-A099-F0CEF10EE27F Q27674710-D204D7EC-3E39-4030-A0AF-0160F07EF546 Q27676915-84F0BFE7-78D1-4FE1-B6F5-D71968E24CDF Q27679876-1531D271-2073-4E1C-B0F7-B07C8FB93FDD Q27679878-8D9C1C57-992B-4EFE-B925-F704BE6E1931 Q27680134-C41293A9-3370-4B08-A66D-CE888F436FFF Q27680405-FF8175AB-FE1D-4FF2-9122-DE78F2F531F0 Q27680427-0576BE76-15D5-4D42-8F28-967629C837BC Q27680635-FF0B159B-944D-43CE-A834-3A02D2A0096B Q27681018-8801FE37-C3A7-4BE9-AC18-2B6A156DBE8E

P2860

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

http://www.wikidata.org/entity/Q27674674

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Inhibition of BET recruitment ...... tment for MLL-fusion leukaemia

@ast

Inhibition of BET recruitment ...... tment for MLL-fusion leukaemia

@en

Inhibition of BET recruitment ...... tment for MLL-fusion leukaemia

@en-gb

Inhibition of BET recruitment ...... tment for MLL-fusion leukaemia

@nl

type

label

Inhibition of BET recruitment ...... tment for MLL-fusion leukaemia

@ast

Inhibition of BET recruitment ...... tment for MLL-fusion leukaemia

@en

Inhibition of BET recruitment ...... tment for MLL-fusion leukaemia

@en-gb

Inhibition of BET recruitment ...... tment for MLL-fusion leukaemia

@nl

prefLabel

Inhibition of BET recruitment ...... tment for MLL-fusion leukaemia

@ast

Inhibition of BET recruitment ...... tment for MLL-fusion leukaemia

@en

Inhibition of BET recruitment ...... tment for MLL-fusion leukaemia

@en-gb

Inhibition of BET recruitment ...... tment for MLL-fusion leukaemia

@nl

P1433

Q27674674-152EF349-1139-4F1D-9F7B-D95831E01DA8

P1476

Q27674674-135D165A-A532-4FBE-B1C6-1B5152F27CE4

P2093

Q27674674-0439DEAB-C36E-42E7-887A-CB0CED3CAD2F

Q27674674-09A6302A-5F6A-462E-8302-B8B41DCF09D1

Q27674674-0A08FABF-A239-497A-A9D4-76F174A041B6

Q27674674-0FA28986-91DF-4D2C-A76E-4A4D992BCC8F

Q27674674-31BFDD6F-9F62-4691-86B4-D85D80014801

Q27674674-49E6F126-CF96-4D12-A139-1776280AFF22

Q27674674-4DEFCC36-54F0-459E-8D7B-57DED4942B74

Q27674674-4EB2EF29-DAF8-4DCD-B61F-6D1DDF6843C1

Q27674674-559740A6-5659-4932-8456-E052A96D6DE9

Q27674674-597A1AC0-23E1-4416-A08D-8593616E012E

P2860

Q27674674-00D1B2C5-7AEC-4DC6-BAF5-010E7F2827AE

Q27674674-0196A201-AFFA-46C6-8768-D80810208FCF

Q27674674-0464A61C-49BC-44C9-83CA-E0CF9A3C0F26

Q27674674-0A94024A-0F6B-45A9-A1C1-E6B7292E24BE

Q27674674-12859D0B-6899-4B75-A908-9CB1A27D06B4

Q27674674-17065A1A-B21E-4C3B-B063-725EE90594A2

Q27674674-276D5C0A-006F-48C5-88D4-4A0B38AECC23

Q27674674-2FB73FC7-09D8-47CA-93B4-7D09D8D5FC6B

Q27674674-3305680C-BA85-414A-BF35-7A09458620E3

Q27674674-4B97F8C8-EAD9-4838-871E-1A25EF53ED89

P2888

Q27674674-4CF7537E-C734-4F37-AB7C-BDE253A0A026

P304

Q27674674-C11D9D07-45E9-4927-B3BC-174FBB63D8A0

P31

Q27674674-08A00647-966B-41C9-B908-C713B25E1744

P3181

Q27674674-472B0F63-F8A0-4187-BDB4-35059DD0F5A7

P356

Q27674674-29E7B33E-A6F0-4F8C-9E84-BE04E4B28AAA

P407

Q27674674-84257E1B-DD11-48E3-A054-8D3EAF84C1FB

P433

Q27674674-F5155B44-1270-4CF0-B5F0-8BBE98795582

P478

Q27674674-9C5696FB-0730-49F2-BCC8-95B43CFFDC20

P50

Q27674674-1BA2B7DE-F376-4E96-B54B-151FDA98243A

Q27674674-50E4EBE7-E3A7-424F-8138-EA86F18126B8

Q27674674-57467957-9528-48C4-809C-1C4A90D21565

Q27674674-B5ED076B-9AC6-4653-83D2-A3DDE8DE6A8E

Q27674674-BE64400A-7494-4D32-A96D-2B0A372ECF3A

Q27674674-F9A31827-B217-4607-BB9D-51D26D30DE5F

Q27674674-FBA1C8DD-D88A-4035-9D06-1A4CA872513D

P577

Q27674674-EC29856E-ADFF-4531-9D3A-B5312461F857

P5875

Q27674674-C97D7809-E816-4FAF-93A5-72119AA7230C

P6179

Q27674674-A80F0E87-0187-4886-9F42-27E138E0F26F

P698

Q27674674-202D5D97-D467-481A-B77E-7327BE66BEF2

P921

Q27674674-74E26E29-0F87-4BA0-90DE-7580735865A6

P932

Q27674674-15F2E19E-FC8F-4266-A684-B4A73BEAFF06

P3181

P356

P1433

P1476

Inhibition of BET recruitment ...... tment for MLL-fusion leukaemia

@en

P2093

Alan K Burnett

http://www.w3.org/2001/XMLSchema#string

Antje Dittmann

http://www.w3.org/2001/XMLSchema#string

Carola Huthmacher

http://www.w3.org/2001/XMLSchema#string

Chun-wa Chung

http://www.w3.org/2001/XMLSchema#string

Dave Lugo

http://www.w3.org/2001/XMLSchema#string

Emma Gudgin

http://www.w3.org/2001/XMLSchema#string

Emma J Roberts

http://www.w3.org/2001/XMLSchema#string

George Giotopoulos

http://www.w3.org/2001/XMLSchema#string

Kevin Lee

http://www.w3.org/2001/XMLSchema#string

Konstanze Doehner

http://www.w3.org/2001/XMLSchema#string

P2860

A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription

Selective inhibition of BET bromodomains

The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription

JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin

The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis

Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes

A Mammalian bromodomain protein, brd4, interacts with replication factor C and inhibits progression to S phase

Suppression of inflammation by a synthetic histone mimic

Discovery and characterization of small molecule inhibitors of the BET family bromodomains

Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4

P2888

P304

529-533

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

24813

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NATURE10509

http://www.w3.org/2001/XMLSchema#string

P407

P433

7370

http://www.w3.org/2001/XMLSchema#string

P478

478

http://www.w3.org/2001/XMLSchema#string

P50

Tony Kouzarides

Olivier Mirguet

P577

2011-10-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51687959

http://www.w3.org/2001/XMLSchema#string

P6179

1026728956

http://www.w3.org/2001/XMLSchema#string

P698

21964340

http://www.w3.org/2001/XMLSchema#string

P921

P932

3679520

http://www.w3.org/2001/XMLSchema#string